Michele Holcomb Purchases 93,944 Shares of PureTech Health (LON:PRTC) Stock

PureTech Health plc (LON:PRTC) insider Michele Holcomb bought 93,944 shares of the firm’s stock in a transaction dated Wednesday, July 29th. The stock was bought at an average cost of GBX 1 per share, with a total value of £939.44.

Michele Holcomb also recently made the following trade(s):

• On Wednesday, July 8th, Michele Holcomb acquired 31,481 shares of PureTech Health stock. The stock was purchased at an average cost of GBX 119 per share, with a total value of £37,462.39.

PureTech Health Stock Down 0.4%

Shares of PRTC traded down GBX 0.48 during mid-day trading on Friday, reaching GBX 119.12. 512,639 shares of the stock traded hands, compared to its average volume of 1,072,302. The stock has a fifty day simple moving average of GBX 127.71 and a 200 day simple moving average of GBX 126.71. PureTech Health plc has a 12-month low of GBX 104.71 and a 12-month high of GBX 146.40. The company has a quick ratio of 2.51, a current ratio of 6.59 and a debt-to-equity ratio of 6.33. The firm has a market cap of £289.96 million, a price-to-earnings ratio of -2.59 and a beta of 0.79.

Wall Street Analyst Weigh In

Separately, Peel Hunt reiterated a “buy” rating and issued a GBX 508 price objective on shares of PureTech Health in a report on Monday, July 13th. One investment analyst has rated the stock with a Buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of GBX 508.

About PureTech Health

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule. It is also developing technology and products for screening, diagnosis, and treatment of neurological disorders, such as ADHD, autism, and depression through computer software; noninvasive neurostimulation treatment for psychiatric disorders; and combination therapy for schizophrenia.